What is William Blair's Forecast for Genmab A/S Q3 Earnings?

Key Points

• William Blair has raised its Q3 2025 earnings estimates for Genmab A/S to $0.46 per share, up from the previous estimate of $0.44, with a full-year earnings estimate of $1.45 per share.
• Genmab A/S's stock has experienced a 5.6% decline recently, with a current market price of $21.43 and a consensus price target of $37.80.
• Institutional investors have significantly increased their stakes in Genmab A/S, demonstrating confidence in the company's potential, particularly as the stock has a consensus rating of "Moderate Buy."

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at William Blair raised their Q3 2025 earnings estimates for shares of Genmab A/S in a note issued to investors on Thursday, August 7th. William Blair analyst M. Phipps now anticipates that the company will earn $0.46 per share for the quarter, up from their prior estimate of $0.44. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's FY2025 earnings at $1.72 EPS, FY2026 earnings at $1.79 EPS, FY2027 earnings at $2.43 EPS and FY2028 earnings at $3.25 EPS.

Other equities research analysts have also recently issued reports about the stock. Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $37.80.

Genmab A/S Stock Down 5.6%

Shares of Genmab A/S stock opened at $21.43 on Monday. The business has a fifty day simple moving average of $21.74 and a 200-day simple moving average of $20.86. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $27.94. The firm has a market cap of $13.75 billion, a price-to-earnings ratio of 10.77, a price-to-earnings-growth ratio of 6.35 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after buying an additional 394,670 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Genmab A/S by 20.4% during the fourth quarter. Franklin Resources Inc. now owns 30,896 shares of the company's stock valued at $645,000 after acquiring an additional 5,233 shares during the period. Cerity Partners LLC lifted its position in shares of Genmab A/S by 6.8% in the 4th quarter. Cerity Partners LLC now owns 51,264 shares of the company's stock valued at $1,070,000 after acquiring an additional 3,261 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Genmab A/S in the 4th quarter worth approximately $2,463,000. Finally, Barclays PLC grew its position in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.